The position
is anchored in the Kidney Biology department that is part of Type 1 Diabetes and Kidney Disease Research within Global Drug Discovery, Novo Nordisk A/S. As part of Novo Nordisk’s strategy within chronic metabolic diseases, we are focusing on target identification, target validation, and pre-clinical characterization of new assets intended to become novel treatment options for patients living with cardiometabolic diseases. In close collaboration with our colleagues, we are working in an organ-centric and disease agnostic manner to develop, characterize, and utilize in vitro tools to elucidate mode-of-action and profiling of novel biology and molecules for early evaluation of drug candidates.Husk at skrive i din ansøgning, at du så jobbet hos Ofir